Start Your NewsReadery Pro FREE TRIAL!

Register and verify your email address to start your NewsReadery Pro FREE TRIAL today!

Login / Register

stocktitan.net / Share Newsitem

View, share or embed this newsitem using the details below.
FDA issues Complete Response Letter for Lexicon's diabetes drug Zynquista. Company pivots to promising LX9211 development for neuropathic pain, with key data expected Q1 2025.
Continue
Please wait ...